Forte Biosciences, Inc. entered into a definitive merger agreement on July 26, 2026, with argenx BV and its subsidiary, Avena Merger Sub Inc. Under the terms of the agreement, argenx will acquire Forte Biosciences in a two-step transaction involving a cash tender offer followed by a merger. The offer price is $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. The transaction is expected to close in Q3 2026, subject to customary closing conditions and a minimum tender requirement of a majority of outstanding shares. Forte Biosciences is a clinical-stage biopharmaceutical company developing autoimmune therapies.

Forte Biosciences, Inc. announced positive results from its FB102 double-blind placebo-controlled Phase 1b study in vitiligo. The company hosted a conference call on July 9, 2026, to review the clinical trial data presentation. Forte Biosciences, Inc. is a biotechnology company focused on developing therapeutic solutions for skin diseases.